https://www.indianpharmapost.com/sms-lifesciences-india-posts-q1-fy24-consolidated-loss-at-rs-179-cr-145072023-08-10T00:00:00+05:30always0.9https://www.indianpharmapost.com/granules-india-posts-q1-fy24-revenue-from-operations-at-rs-9855-cr-145082023-08-10T00:00:00+05:30always0.9https://www.indianpharmapost.com/hester-biosciences-posts-q1-fy24-consolidated-pat-at-rs-586-cr-145092023-08-10T00:00:00+05:30always0.9https://www.indianpharmapost.com/suven-life-sciences-posts-q1-fy24-consolidated-loss-at-rs-2409-cr-145102023-08-10T00:00:00+05:30always0.9https://www.indianpharmapost.com/natural-capsules-q1-fy24-consolidated-pat-falls-to-rs-182-cr-145112023-08-10T00:00:00+05:30always0.9https://www.indianpharmapost.com/abbott-indias-q1-fy24-pat-up-at-rs-29024-cr-145122023-08-10T00:00:00+05:30always0.9https://www.indianpharmapost.com/iol-chemicals-and-pharmaceuticals-posts-q1-fy24-consolidated-pat-at-rs-4586-cr-145132023-08-10T00:00:00+05:30always0.9https://www.indianpharmapost.com/dishman-carbogen-amcis-posts-q1-fy24-consolidated-pat-at-rs-17-cr-145142023-08-10T00:00:00+05:30always0.9https://www.indianpharmapost.com/lincoln-pharmaceuticals-posts-q1-fy24-standalone-net-profit-at-rs-1901-cr-145152023-08-10T00:00:00+05:30always0.9